| Hazard Information | Back Directory | [Uses]
Bavituximab (Anti-Human Phosphatidylserine Recombinant Antibody) is a phosphatidylserine (PS)-targeting monoclonal antibody, suppresses tumor growth by targeting tumor vasculature and reactivating antitumor immunity. Bavituximab plus Paclitaxel.html" class="link-product" target="_blank">Paclitaxel (HY-B0015) and Carboplatin.html" class="link-product" target="_blank">Carboplatin (HY-17393), have enhanced inhibition on non-small-cell lung cancer[1]. | [in vivo]
Sorafenib induces exposure of anionic phospholipids in tumor model in mice. Bavituximab (100 μg/mouse; i.v.; single dose; 48 h after Sorafenib treatment) traces phosphatidylserine exposure in vivo[2].
| Animal Model: | Mice bearing subcutaneous PLC/PRF/5, C3A, and Huh7 tumors[2] | | Dosage: | 100 μg/mouse (Bavituximab/β2GP1) | | Administration: | Intravenous injection single dose; 48 h after sorafenib treatment (100 mg/kg; p.o.; single dose) | | Result: | Traced phosphatidylserine exposure in vivo in mice with tumors. |
| [References]
[1] Digumarti R, et al. Bavituximab plus paclitaxel and carboplatin for the treatment of advanced non-small-cell lung cancer. Lung Cancer. 2014 Nov;86(2):231-6. DOI:10.1016/j.lungcan.2014.08.010
[2] Cheng X, et al. Antibody-Mediated Blockade of Phosphatidylserine Enhances the Antitumor Effect of Sorafenib in Hepatocellular Carcinomas Xenografts. Ann Surg Oncol. 2016 Dec;23(Suppl 5):583-591. DOI:10.1245/s10434-016-5107-5 |
|
| Company Name: |
LGM Pharma
|
| Tel: |
1-(800)-881-8210 |
| Website: |
www.lgmpharma.com |
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
| Company Name: |
NCE Biomedical Co.,Ltd.
|
| Tel: |
4000-027-021 |24 +86-13986109188 | +86-15623472865 | +81-08033611988 |
| Website: |
www.chemicalbook.com/ShowSupplierProductsList15748/0_EN.htm |
| Company Name: |
Biolab Reagents
|
| Tel: |
027-65279366 18108604356 |
| Website: |
www.biolabreagent.com/ |
|